Raloxifene and prevention of vertebral fracture (cont'd): mainly when oestrogen is contraindicated.
(1) The three-year results of a clinical trial confirm that raloxifene is the second-line treatment for primary and secondary prevention of vertebral fracture in postmenopausal women at risk of osteoporosis. They also confirm that raloxifene increases the risks of thromboembolism and diabetes.